SGSe-Il Go

Se-Il Go

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Se-Il Go has a total of 141 co-authors. Here are the top co-authors by number of shared publications:

  • Jung Hun Kang

    Department of Internal Medicine, Gyeongsang National University College of Medicine, Jinju, Korea

    8 shared publications
  • Gyeong-Won Lee

    Gyeongsang National University College of Medicine

    5 shared publications
  • Won Sup Lee

    Department of Internal Medicine, Institute of Medical Science, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, 15 Jinju-daero 816 Beon-gil, Jinju 52727, Republic of Korea

    5 shared publications
  • Jung Hun Kang

    Department of Internal Medicine, Gyeongsang National University College of Medicine , Jinju

    4 shared publications
  • Chang Min Lee

    Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea

    3 shared publications
  • Gon Sup Kim

    Research Institute of Life science and College of Veterinary Medicine, Gyeongsang National University, Jinju, 52828, Republic of Korea.

    3 shared publications

Latest Publications

  • Open Access

    CD40 Agonists in Pancreatic Cancer: From Immune Priming to Clinical Translation

    by Myoung Hee Kang, Se-Il Go, Won Sup Lee

    Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly desmoplastic and immunosuppressive tumor microenvironment (TME) that limits immune-cell infiltration, impairs antigen presentation, and promotes tumor-supportive myeloid responses. CD40 agonism offers a distinct immunotherapeutic strategy by activating macrophages and antigen-presenting cells (APCs), enhancing antigen presentation, and promoting innate and adaptive antitumor immunity. Preclinical studies have demonstrated macrophage-dependent tumor regression and stromal remodeling, while combination with chemotherapy can enhance antigen release and subsequent immune priming. Clinical studies of CD40 agonists, including sotigalimab, mitazalimab, and selicrelumab, have demonstrated immune and TME remodeling, but consistent survival benefit has not been established in unselected patients. Differences in treatment context, chemotherapy backbone, treatment sequence, and antibody architecture may contribute to variable clinical outcomes. Emerging evidence indicates that limited therapeutic activity may reflect multiple factors, including APC deficiency, persistent immunosuppression, inadequate effector responses, stromal and spatial immune exclusion, and pharmacologic limitations related to Fcγ receptor engagement and systemic toxicity. Future development should therefore emphasize biomarker-guided patient selection, rational treatment sequencing, spatially controlled CD40 activation, and mechanistically matched combination strategies. Integration of immune, molecular, and pharmacodynamic biomarkers, together with next-generation CD40 agonists, may help translate CD40-mediated immune remodeling into more durable clinical benefit in PDAC.

  • Open Access

    Low pectoralis muscle index is associated with inferior survival in standard-risk newly diagnosed multiple myeloma

    by Se-Il Go, Seok-Ho Yoon, Sungwoo Park, Bong-Hoi Choi, Myoung Hee Kang, Eun-Jeong Jeong, Byeong Sun Moon, Gyeong-Won Lee

    Background: The severity and prognostic significance of sarcopenia in hematologic malignancies, particularly newly diagnosed multiple myeloma (NDMM), remain insufficiently characterized. Objectives: We aimed to compare the pectoralis muscle index (PMI) distribution in NDMM with that in an unmatched diffuse large B-cell lymphoma (DLBCL) reference cohort and to assess the prognostic value of PMI in NDMM. Design: A retrospective cohort study with an independent reference cohort. Methods: The study included 179 patients with NDMM. PMI was measured at the T4 level using the non-contrast CT component of baseline PET-CT. PMI values were compared with those from an independent cohort of 305 patients with DLBCL. Within the NDMM cohort, patients were stratified into low and high PMI groups using study-derived sex-specific cutoffs. Associations between PMI and clinical outcomes, including overall survival (OS) and time to next treatment (TTNT), were analyzed with subgroup analyses according to Revised International Staging System (R-ISS). Results: Median PMI was significantly lower in the NDMM cohort than in the DLBCL reference cohort for both males (4.19 vs. 5.58 cm 2 /m 2 , p < 0.001) and females (3.25 vs. 4.14 cm 2 /m 2 , p < 0.001). In multivariable analysis adjusting for age, sex, body mass index, and inflammatory and nutritional markers, NDMM remained independently associated with lower PMI (β = −0.88). Within the NDMM cohort, low PMI was independently associated with inferior OS (adjusted HR, 2.79; 95% CI, 1.42-5.47; p = 0.003; 3-year OS, 48% vs. 78%). Patients with low PMI also had shorter TTNT (3-year TTNT, 14% vs. 45%). These associations appeared more evident among patients with R-ISS stage I-II disease, whereas no significant differences were observed in those with R-ISS stage III disease. Conclusion: PMI may serve as a practical imaging-based measure of sarcopenia with potential prognostic relevance in NDMM, particularly among patients with R-ISS stage I-II disease.

  • Corneal reflex: novel strong prognostic marker for imminent death

    by Se-Il Go, Gyeong-Won Lee, Byeong Sun Moon, Jung Woo Choi, Seong-Je Kim, Jung Hun Kang

    Objectives: This study aimed to evaluate the prognostic significance of the corneal reflex in predicting death within 24 hours among terminally ill patients with cancer. Methods: This prospective observational study was conducted with patients with advanced cancer admitted to the hospice centre of Gyeongsang National University Hospital who were in the phase of impending death. Corneal reflex and other end-of-life signs were assessed three times daily by trained nurses using standardised criteria. Mixed-effects logistic regression was used to identify predictors of death within 24 hours, and diagnostic performance was examined for 24–96 hours. Results: A total of 665 observations was analysed. Absence of corneal reflex was strongly associated with death within 24 hours (OR 5.48, p<0.001), with a 24-hour mortality rate of 70.7%. It showed high specificity (85.0%) and positive predictive value (70.7%). Even among patients with a Richmond Agitation-Sedation Scale score of −4 or −5, absence of the corneal reflex remained a significant predictor of 24-hour mortality (71.2% vs 37.1%, p<0.001). Other significant predictors included peripheral cyanosis, oxygen desaturation and low blood pressure. Conclusions: Absence of corneal reflex is a specific and clinically useful sign of imminent death within 24 hours in terminally ill patients with cancer, supporting its application in end-of-life prognostication and decision-making.

  • Open Access

    Dramatic Response to Palliative Radiotherapy in Advanced Eyelid Squamous Cell Carcinoma: A Case Report

    by In Bong Ha, Byeong Sun Moon, Se-Il Go, Jung Hun Kang

    In Bong Ha, M.D., Byeong Sun Moon, M.D., Se-Il Go, M.D., Ph.D. and Jung Hun Kang, M.D., Ph.D.. J Hosp Palliat Care 2025;28:180-3. https://doi.org/10.14475/jhpc.2025.28.4.180

  • Open Access

    Sarcopenia in Terminally Ill Patients with Cancer: Clinical Implications, Diagnostic Challenges, and Management Strategies

    by Se-Il Go, Myoung Hee Kang, Hoon-Gu Kim

    Se-Il Go, M.D.1, Myoung Hee Kang, M.D.1 and Hoon-Gu Kim, M.D., Ph.D.. J Hosp Palliat Care 2025;28:10-7. https://doi.org/10.14475/jhpc.2025.28.1.10


  • Open Access

    Efficacy of transdermal buprenorphine patch for managing withdrawal symptoms in patients with cancer physically dependent on prescription opioids

    by Jung Hun Kang, Kyung Hee Lee, Seok Jae Huh, Seong-Hoon Shin, Il Hwan Kim, In Gyu Hwang, Dong-Hoe Koo, Dongyun Lee, Su-Jin Koh, Seyoung Seo, et al.

    The physical dependence on prescription opioids among cancer survivors remains an under-investigated area, with a scarcity of well-designed prospective studies. This single-arm, phase-2 clinical trial in Korea assessed the efficacy and safety of a transdermal buprenorphine patch (TBP) in managing physical dependence on prescription opioids in cancer survivors, as confirmed through the DSM-5 criteria or psychiatric consultation for opioid withdrawal. This study involved a 4-phase treatment protocol of screening, induction/stabilization, discontinuation, and monitoring. The primary outcome was the rate of successful opioid discontinuation, as measured by a negative urine-drug screening at 8 weeks. Key secondary outcomes included the resumption of prescribed opioids, changes in both the Clinical Opioid Withdrawal Scale (COWS) and morphine equivalent daily dose (MEDD), and assessments related to the psychological and physiological aspects of dependence and safety. Thirty-one participants were enrolled. In the intention-to-treat population, the success rate of opioid discontinuation was 58%, with only 2 participants experiencing a resumption of prescribed opioids. Significant reductions were observed in MEDD, which decreased from 98 to 26 mg/day (P < .001), and COWS scores, which decreased from 5.5 to 2.8 (P < .001). Desire to use opioids reduced from 7.0 to 3.0 on a 10-point numeric rating scale (P < .001). Toxicities related to TBP were mild and manageable, without severe precipitated withdrawal symptoms. TBP may be considered as an alternative therapeutic option in cancer survivors physically dependent on prescription opioids, especially where sublingual formulations are unavailable.


  • Open Access

    Lipocalin‐2 as a prognostic biomarker and its association with systemic inflammation in small cell lung cancer

    by Se‐Il Go, Jung Wook Yang, Woo Je Lee, Eun Jeong Jeong, Sungwoo Park, Gyeong‐Won Lee

    Background: Systemic inflammation is believed to contribute to small cell lung cancer (SCLC) progression, but the underlying relationship remains unclear. Lipocalin‐2, a potential biomarker of inflammation, has been implicated in various cancers but its prognostic value in SCLC is underexplored.Methods: We retrospectively analyzed 191 patients with SCLC (72 with limited‐stage [LD] and 119 with extensive‐stage) treated using platinum‐based chemotherapy. Lipocalin‐2 expression was evaluated using immunohistochemistry. Optimal cutoff values for lipocalin‐2 and neutrophil‐to‐lymphocyte ratio (NLR) were determined using time‐dependent receiver operating characteristic curve analysis. The pectoralis muscle index was used to assess sarcopenia.Results: In LD‐SCLC, high lipocalin‐2 expression was associated with worse progression‐free survival (PFS; median: 7.0 vs. 15.9 months, p = 0.015) and overall survival (OS; median: 12.9 vs. 30.3 months, p = 0.035) compared with low lipocalin‐2 expression. Patients were stratified into three prognostic groups by combining lipocalin‐2 with NLR: low lipocalin‐2/low NLR, high lipocalin‐2/low NLR or low lipocalin‐2/high NLR, and high lipocalin‐2/high NLR (median PFS: 17.3 vs. 11.0 vs. 6.3 months, p = 0.004; median OS: 30.5 vs. 17.3 vs. 8.6 months, p = 0.002). Similar trends were observed when combining lipocalin‐2 with the pectoralis muscle index. High lipocalin‐2 expression was also associated with lower complete response rates (18.9% vs. 34.3%, p = 0.035). No significant prognostic implications were found for lipocalin‐2 in extensive‐stage SCLC.Conclusions: High lipocalin‐2 expression is potentially associated with poorer survival in LD‐SCLC. Combining lipocalin‐2 with other inflammation‐related markers could improve prognostic stratification.


  • Clinical implication of megestrol acetate in metastatic gastric cancer: a big data analysis from Health Insurance Review and Assessment (HIRA) database

    by Chang Min Lee, Jung Hun Kang, Se-Il Go

    Objective Megestrol acetate (MA) is used to manage anorexia and cachexia in patients with advanced cancer. This study investigated the prescription patterns of MA in patients with metastatic gastric cancer, as well as evaluated its impact on survival outcomes and the incidence of venous thromboembolism (VTE). Methods A Health Insurance Review and Assessment (HIRA) service database was used to investigate differences in baseline characteristics, survival, and the incidence of VTE according to MA prescription patterns (i.e., prescription vs. no prescription) in patients diagnosed with metastatic gastric cancer from July 2014 to December 2015. Results A total of 1938 patients were included in this study. In total, 65% of the patients were prescribed MA. Older age, treatment in tertiary hospitals, and palliative chemotherapy were statistically significant predictive factors for MA prescription. Continuous prescription of MA was observed in 37% of patients. There was no statistically significant difference in survival between the MA and non-MA prescription groups on multivariate analysis. Among the 1427 patients included in the analysis for VTE incidence, 4.3% and 2.9% were diagnosed with VTE during the follow-up period in the MA and non-MA prescription groups, respectively. However, there was no statistically significant difference in VTE diagnosis between the groups on multivariate analysis. Conclusion MA is commonly prescribed for metastatic gastric cancer, especially in elderly patients and those undergoing palliative chemotherapy, without significantly affecting survival or VTE risk.


  • Open Access

    Proportion of Non-Medical Opioid Use of Prescription Opioids among Cancer Patients in Korea

    by Se-Il Go, Jung Hye Kwon, Sung Woo Park, Gyeong-Won Lee, Jung Hun Kang, Eduardo Bruera

    Se-Il Go, M.D., Jung Hye Kwon, M.D., Sung Woo Park, M.D., Gyeong-Won Lee, M.D., Jung Hun Kang, M.D. and Eduardo Bruera, M.D.. J Hosp Palliat Care 2023;26:185-9. https://doi.org/10.14475/jhpc.2023.26.4.185